Journal
BEHAVIOURAL BRAIN RESEARCH
Volume 291, Issue -, Pages 80-88Publisher
ELSEVIER
DOI: 10.1016/j.bbr.2015.04.038
Keywords
Oxaliplatin; Chemotherapy; Cognition; Rat; Peripheral neuropathy; Mechanical allodynia
Categories
Funding
- Cancer Institute NSW, Australia
Ask authors/readers for more resources
Chemotherapy treatment is associated with cognitive dysfunction in cancer survivors after treatment completion. The duration of these impairments is unclear. Therefore this paper aims to evaluate the lasting impact of varying doses of the chemotherapy oxaliplatin (OX) on cognition and peripheral neuropathy. In Experiment 1 rats were treated once a week for 3 weeks with either physiological saline (control) or 6 mg/kg OX i.p. and were assessed for peripheral neuropathy, using von Frey filaments, and cognitive function, using novel object and location recognition, up to 2 weeks after treatment completion. For Experiment 2 rats received 3 weekly i.p. injections of either physiological saline (control), 0.6 mg/kg, 2 mg/kg or 6 mg/kg OX and assessed for peripheral neuropathy and cognitive function up toll months after treatment completion. Systemic OX treatment induced lasting effects on cognitive function at 11 months after treatment, and peripheral neuropathy at 1 month after treatment and these were dose dependent; higher doses of OX resulted in worse cognitive outcomes and more severe peripheral neuropathy. (C) 2015 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available